Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes
Linda A. Jahn, LEE HARTLINE, Thi Thuy Dung Nguyen, Kevin W. Aylor, William B. Horton, Zhenqi Liu, Eugene J. Barrett
Abstract
The physiological underpinnings of the cardiovascular benefits of SGLT2 inhibitors remain uncertain. We tested whether empagliflozin mitigates vascular insulin resistance in patients with type 2 diabetes. Aortic and peripheral systolic, diastolic, mean and pulse pressures, endothelial function, vascular stiffness, and heart and muscle microvascular perfusion were measured before and during an insulin infusion at baseline and after 12 wk of empagliflozin. After empagliflozin, vascular responses to insulin improved dramatically.
Topics & Concepts
EmpagliflozinMedicineInternal medicineCardiologyType 2 diabetesInsulin resistanceDiabetes mellitusPerfusionInsulinBlood pressureHemodynamicsVascular resistanceEndocrinologyDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerPancreatic function and diabetes